The goal of current strategies for NB treatment is to decrease therapy- and minimize chemotherapy-related toxicity for patients from low and intermediate NB risk groups, whereas concerning high risk NB cases, present and upcoming trials are devoted to the development of novel immunotherapies, inhibitors of aberrant pathways (such as MYC and ALK), and radioisotope-containing regimens. Here, MYC is linked to neuroblastoma.